Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Characterization of a Novel Bi-genic Mouse Model of Parkinsonism and Dementia with Lewy Bodies

FY 2014-15

Summary
Parkinson’s disease (PD) and several related neurodegenerative diseases such as dementia, have no cure, worsen with time and are responsible for a poor quality of life in those affected. Current treatments aim to reduce the disabling motor symptoms but do not change the course of the disease or help to reduce the non-motor symptoms of PD, such as issues with memory or learning. My goal is to help develop new treatments that fill this void, by finding a suitable animal model of the symptoms and pathology of PD. The lack of a suitable animal model has been a major problem that has prevented real progress in the development of novel curative therapies for PD. Our team has recently developed a transgenic mouse, the SYNERGY mouse, which combines two major genetic risk factors for PD. I hypothesize that SYNERGY mice will develop the brain pathology and behavioural deficits associated with PD and its dementias. The genetic mutations in SYNERGY mice individually promote the aggregation of the neuronal protein a-synuclein, which is a characteristic pathology of PD. I believe that these a-synuclein aggregates will cause the SYNERGY mouse to have deficits in their ability to smell and to perform motor and learning tasks. To study this, I will measure SYNERGY mouse behaviour, using many standard behavior tests, and a-synuclein levels in the brain throughout the lifespan. I expect SYNERGY behavior deficits to worsen with age and correlate to high levels of a-synuclein aggregation in the brain. Taken together, the SYNERGY mouse has the potential to be a very valuable tool for studying disease causes and new curative drugs for these devastating neurological disorders.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
331270
Name
Fitzpatrick Megan E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of a Novel Bi-genic Mouse Model of Parkinsonism and Dementia with Lewy Bodies
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alpha Synuclein; Behavioural Studies; Dementia; Dementia With Lewy Bodies; Glucocerebrosidase; Mouse Model; Parkinson'S Disease; Synucleinopathy
Abstract
Parkinson’s disease (PD) and several related neurodegenerative diseases such as dementia, have no cure, worsen with time and are responsible for a poor quality of life in those affected. Current treatments aim to reduce the disabling motor symptoms but do not change the course of the disease or help to reduce the non-motor symptoms of PD, such as issues with memory or learning. My goal is to help develop new treatments that fill this void, by finding a suitable animal model of the symptoms and pathology of PD. The lack of a suitable animal model has been a major problem that has prevented real progress in the development of novel curative therapies for PD. Our team has recently developed a transgenic mouse, the SYNERGY mouse, which combines two major genetic risk factors for PD. I hypothesize that SYNERGY mice will develop the brain pathology and behavioural deficits associated with PD and its dementias. The genetic mutations in SYNERGY mice individually promote the aggregation of the neuronal protein a-synuclein, which is a characteristic pathology of PD. I believe that these a-synuclein aggregates will cause the SYNERGY mouse to have deficits in their ability to smell and to perform motor and learning tasks. To study this, I will measure SYNERGY mouse behaviour, using many standard behavior tests, and a-synuclein levels in the brain throughout the lifespan. I expect SYNERGY behavior deficits to worsen with age and correlate to high levels of a-synuclein aggregation in the brain. Taken together, the SYNERGY mouse has the potential to be a very valuable tool for studying disease causes and new curative drugs for these devastating neurological disorders.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fitzpatrick, Megan E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~